Survivin-targeted immune therapy for newly diagnosed glioblastoma
Part of Cancer clinical trials.
This trial tests a new immunotherapy called PERCELLVAC-Sur that targets a protein (Survivin) found in glioblastoma tumors. It is given after standard radiation and chemotherapy, and the goal is to see if it helps the immune system fight the cancer more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a new diagnosis of glioblastoma (GBM) that is grade 4 (the most aggressive type), confirmed by a biopsy or surgery.
- Your tumor must test positive for a protein called Survivin (done with a special lab test on your tumor sample).
- You must have completed the standard 6 weeks of radiation with temozolomide chemotherapy, with at least 5 weeks of the chemo. (If you had surgery, this must have started within 50 days after surgery.)
- You must be able to do most of your daily activities with little help (KPS score of 70 or higher).
- You cannot take more than 2 mg of dexamethasone (a steroid) per day, or have taken more than 10 mg in a single dose in the last month.
- You must not have other serious illnesses, infections (like HIV, hepatitis), or be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized immune therapy made from your own cells (dendritic cells) that target a protein called survivin in glioblastoma. It's given after standard radiation and chemotherapy, and may help your immune system fight the cancer.
This trial tests a personalized vaccine made from your own immune cells (dendritic cells) to treat glioblastoma that has come back after standard treatment. The vaccine is designed to help your immune system recognize and attack your tumor.
This trial tests whether adding a personalized vaccine made from your own immune cells and tumor can help standard chemotherapy and radiation work better against glioblastoma. It is for patients who have already had surgery and are starting or have just finished their first round of chemoradiation.
This trial tests a more intense chemotherapy plan for people with glioblastoma who had only partial removal of their tumor or whose tumor grew back quickly. The goal is to see if this approach can improve outcomes.
This trial tests a personalized vaccine made from your own immune cells to see if it can help treat glioblastoma. If you are currently getting standard treatments like surgery, chemo, and radiation, you may be able to join.
This trial tests a new vaccine (UCPVax) with or without pembrolizumab (an immunotherapy) given after standard radiation and chemotherapy for people with a specific type of glioblastoma (MGMT unmethylated). The goal is to see if adding these treatments can help prevent the cancer from coming back.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.